Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 28Prostatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Lung Neoplasms 6Uterine Cervical Neoplasms 5Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasms 3Liposarcoma, Myxoid 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Radiation Injuries 2Neurofibrosarcoma 2Neoplasm Metastasis 2Melanoma 2Lymphatic Metastasis 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Cholangiocarcinoma 2

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Radiation Dose Hypofractionation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT05530200 2022-09-07

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
56 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡